ArticleIJTLD open2025
Diagnostic accuracy of RISK6 assay in childhood pulmonary TB.
Article in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring non-sputum biosignatures for tuberculosis triage and diagnosis in children living with HIV.Expert review of molecular diagnostics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe WHO recently updated the target product profile (TPP) for TB identification at the peripheral level to guide test development.
methodsWe conducted a prospective diagnostic accuracy study among outpatients under 15 years old with presumed pulmonary TB at the International Centre for Diarrheal Disease Research, Bangladesh (icddr,b) Dhaka Hospital. We evaluated the accuracy of the RISK6 assay and performed a cost-per-TB case identification analysis.
resultsOf 365 enrolled children, 68 had microbiologically confirmed TB, 94 had unconfirmed TB and 203 were unlikely to have TB. RISK6 did not meet the TPP for TB diagnosis in children but in presumptive pulmonary TB individuals ≤ 12 months, the assay outperformed (32/42) both the Mantoux test (7/42) and chest X-ray (11/42) in correctly referring individuals for confirmatory testing. RISK6, alone or in combination with Mantoux test, was the most cost-effective strategy for identifying and confirming TB, with a cost as low as $US132.00 in children > 12 months.
conclusionAlthough RISK6 did not meet the WHO TPP for TB diagnosis, it shows promise as a triage test, especially for children ≤ 12 months, and could serve as a decision-support tool in integrated treatment algorithms recommended by the WHO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.